[Biventricular thrombus resolution and antibody formation during lepirudin therapy. Comment on the article from DMW 28-29/2003].
Nowak
Götz
G
D000818:Animals; D000917:Antibody Formation; D000925:Anticoagulants / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000276:immunology; D004285:Dogs; D006629:Hirudins / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology*; D006801:Humans; D008297:Male; D051381:Rats; D011994:Recombinant Proteins / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D013552:Swine; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D013917:Thrombin; C083544:lepirudin